UB102

UB102 is an experimental biologic drug originally developed by Xi'an Duote Biotechnology. It is described as an **Ang2 modulator** and **VEGF-A modulator**. Ang2 (angiopoietin-2) and VEGF-A (vascular endothelial growth factor A) are both important regulators of angiogenesis (the formation of new blood vessels), with central roles in diseases such as diabetic retinopathy and age-related macular degeneration. The therapeutic strategy of modulating both Ang2 and VEGF-A has been explored for the treatment of ophthalmic vascular diseases, typically aiming to suppress abnormal blood vessel growth and reduce vascular leakage in the retina and choroid.